Digital EEG Frequently Asked Questions PDF  | Print |

The following information is taken from Lexicor Medical Technologies, Inc.

Frequently Asked Questions

What is ADHD?

According to the American Psychiatric Association, ADHD is a neurological disorder that affects 3% - 5% of school age children. It is characterized by developmentally inappropriate impulsivity, inattention, and in some cases, hyperactivity. ADHD tends to persist from childhood through adolescence and many symptoms continue into adulthood. Recent studies estimate that between 30% - 70% of children with ADHD continue to exhibit symptoms as an adult.

Why is ADHD so difficult to assess?

The symptoms of ADHD are similar to those of more than 30 other disorders, each requiring different types of medication/treatment. These include problems ranging from hearing/vision abnormalities or allergies to depression and anxiety.

What is the NeuroLexSM Indicator Report for ADHD?

NeuroLexSM is the first objective tool your health provider can use to provide additional information in the assessment of ADHD. The NeuroLexSM Indicator Report, combined with a thorough evaluation, will lead to a more accurate assessment of ADHD.

Is the use of the NeuroLexSM Indicator Report Changing Lives?

For or patients suspected of having ADHD, NeuroLexSM delivers things that have been missing from ADHD evaluation thus far – objectivity and accuracy. Patients and parents deserve a highly accurate assessment of this disorder, so that the treatment received is justified and appropriate. For patients who are found not to have ADHD, the avoidance of unnecessary medication or expensive treatment provides peace of mind.

Findings Used in NeuroLexSM Indicator Report for ADHD

  • The NeuroLexSM Indicator Report for ADHD is based upon recent studies that collectively suggest ADHD patients have distinct electroencephalographic (EEG) patterns as compared to the normal population.
  • Specifically, ADHD individuals have been found to have increased activity in the theta band and decreased activity in the beta band, resulting in an increase in the ratio of theta power over beta power, or an increased "theta/beta ratio."
  • In addition, research has shown there is a subgroup of ADHD patients who do not show an increase in the theta/beta ratio, but rather display an increase in frontal beta power as compared to normal population.
  • Research has demonstrated that ADHD can be accurately assessed using quantitative EEG data. This classification technique is based on the observation of distinct measurable changes that ADHD patients exhibit in their brain wave activity relative to normal subjects.
  • The NeuroLexSM Indicator Report for ADHD is supported by research studies that show QEEG offers a 90% probability that a person does not have ADHD and a 94% probability that a person does have ADHD with a 96% reliability rate. In addition, the NeuroLexSM Indicator Report for ADHD includes a second analytical technique that further strengthens the accuracy of a professional assessment.

Obtaining Patient Data

Data is collected in our office by a trained technician. A cap (much like a bathing cap) is placed on the patient's head. It is essential that the cap is snug fitting to collect good data for analysis. The technician applies a conductive gel through holes located in the cap. During the actual data collection, the patient is resting with eyes closed and again with eyes open. The entire process is completely non-invasive, and takes approximately one hour to complete.

 

Every digital EEG is read by Dr. Susan Anderson, a board certified neurologist, who also holds a subspeciality in sleep medicine.  A report from Dr. Anderson is included with our findings. 

 

Contact Us

If you are experiencing a problem with scheduling or our services, please email Laura, or contact her at (612) 872-9072 and she will be happy to assist you.

Office Hours : 9am to 5pm | Monday to Friday

Mission Statement

Our goal is to determine the cause of difficulties with attention, learning and/or memory, and to recommend an individualized treatment approach using the most current brain-based research.

Quoted : Dr. Gary Johnson, C.A.L.M. Director